Biotechnology
Biopharmaceutical
Pharmaceutical
TG Therapeutics
$7.499876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$7.49
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.08 (1.12%) Today
+$0.29 (3.96%) After Hours
Why Robinhood?
You can buy or sell TGTX and other stocks, options, ETFs, and crypto commission-free!
About
TG Therapeutics, Inc. Common Stock, also called TG Therapeutics, is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Read More Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
Employees
105
Headquarters
New York, New York
Founded
1993
Market Cap
637.49M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.62M
High Today
$7.51
Low Today
$7.00
Open Price
$7.00
Volume
739.07K
52 Week High
$16.00
52 Week Low
$3.32
Collections
Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Therapy
Technology
News
Seeking AlphaMay 14
TG Therapeutics: Varied Pipeline With 2 Lead Candidates In Late Stage, Low Cash Position
Due to the poor cash position, I am not considering this a major buy at this time. Despite the cash problem, TGTX could be an interesting stock to consider, post dilution and ahead of catalysts. TG Therapeutics (TGTX) is a developing clinical stage company with 2 lead drugs in 4 phase 3 trials in various indications. Both these are mAbs with unique MoAs in immune-oncology, and we have major catalysts ahead within the next year. The stock is trading near its 52-week low, probably due to the one risk we hav...
Yahoo FinanceMay 11
Edited Transcript of TGTX earnings conference call or presentation 10-May-19 12:00pm GMT
Q1 2019 TG Therapeutics Inc Earnings Call NEW YORK May 11, 2019 (Thomson StreetEvents) -- Edited Transcript of TG Therapeutics Inc earnings conference call or presentation Friday, May 10, 2019 at 12:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Jenna Bosco TG Therapeutics, Inc. - VP of IR & Senior VP of Corporate Communicat...
Price Paid on Robinhood
1% Lower
Right Now
52 Week Low
$3.32
Average Price Paid
$7.56
52 Week High
$16.00
Earnings
-$0.68
-$0.59
-$0.51
-$0.42
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.43 per share
Actual
-$0.43 per share